CL2013003646A1 - Compuestos derivados de trans-1-(3s.1r)-6-cloro-3-fenilindan-1-il)-1,2,2-trimetilpiperazina deuterados, con actividad en los receptores 5ht2, d1 y d2; proceso de preparacion; compuesto intermediario; composicion y combinacion farmaceutica; y su uso para el tratamiento de la psicosis, entre otros. - Google Patents
Compuestos derivados de trans-1-(3s.1r)-6-cloro-3-fenilindan-1-il)-1,2,2-trimetilpiperazina deuterados, con actividad en los receptores 5ht2, d1 y d2; proceso de preparacion; compuesto intermediario; composicion y combinacion farmaceutica; y su uso para el tratamiento de la psicosis, entre otros.Info
- Publication number
- CL2013003646A1 CL2013003646A1 CL2013003646A CL2013003646A CL2013003646A1 CL 2013003646 A1 CL2013003646 A1 CL 2013003646A1 CL 2013003646 A CL2013003646 A CL 2013003646A CL 2013003646 A CL2013003646 A CL 2013003646A CL 2013003646 A1 CL2013003646 A1 CL 2013003646A1
- Authority
- CL
- Chile
- Prior art keywords
- psychosis
- treatment
- pharmaceutical composition
- phenylindan
- trimethylpiperazine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
- C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
COMPUESTO DE FÓRMULA Y, DONDE R 1 - R1° SON, DE MODO INDEPENDIENTE, HIDRÓGENO O DEUTERIO, EN DONDE AL MENOS UNO DE R1—R1° COMPRENDE AL MENOS EL 50% DE DEUTERIO O UNA DE SUS SALES POR ADICIÓN DE ÁCIDOS FARMACÉUTICAMENTE ACEPTABLES. COMPOSICIÓN FARMACÉUTICA, QUE COMPRENDE DICHO COMPUESTO Y UNO O VARIOS PORTADORES, DILUYENTES O EXCIPIENTES FARMACÉUTICAMENTE ACEPTABLES. USO DE DICHO COMPUESTO PARA EL TRATAMIENTO DE PSICOSIS, OTRAS ENFERMEDADES QUE INCLUYEN SÍNTOMAS PSICÓTICOS, TRASTORNOS PSICÓTICOS O ENFERMEDADES QUE SE PRESENTAN CON SÍNTOMAS PSICÓTICOS. COMPUESTO INTERMEDIARIO Y PROCESOS PARA LA PREPARACIÓN DE DICHO COMPUESTO.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161498651P | 2011-06-20 | 2011-06-20 | |
US201161537103P | 2011-09-21 | 2011-09-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2013003646A1 true CL2013003646A1 (es) | 2014-07-04 |
Family
ID=46682855
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2013003646A CL2013003646A1 (es) | 2011-06-20 | 2013-12-19 | Compuestos derivados de trans-1-(3s.1r)-6-cloro-3-fenilindan-1-il)-1,2,2-trimetilpiperazina deuterados, con actividad en los receptores 5ht2, d1 y d2; proceso de preparacion; compuesto intermediario; composicion y combinacion farmaceutica; y su uso para el tratamiento de la psicosis, entre otros. |
Country Status (40)
Country | Link |
---|---|
US (8) | US8575174B2 (es) |
EP (4) | EP4215512A1 (es) |
JP (1) | JP5668177B2 (es) |
KR (2) | KR101879474B1 (es) |
CN (1) | CN103649019B (es) |
AP (1) | AP3310A (es) |
AR (1) | AR086987A1 (es) |
AU (1) | AU2012273657B2 (es) |
BR (1) | BR112013031702B1 (es) |
CA (1) | CA2837820C (es) |
CL (1) | CL2013003646A1 (es) |
CO (1) | CO6821965A2 (es) |
CR (1) | CR20130654A (es) |
CY (2) | CY1118158T1 (es) |
DK (2) | DK2720989T3 (es) |
DO (1) | DOP2013000305A (es) |
EA (1) | EA024651B1 (es) |
EC (1) | ECSP14013155A (es) |
ES (3) | ES2939477T3 (es) |
GE (1) | GEP201706655B (es) |
GT (1) | GT201300304A (es) |
HK (1) | HK1197228A1 (es) |
HR (2) | HRP20161348T1 (es) |
HU (2) | HUE044043T2 (es) |
IL (1) | IL229640B (es) |
JO (1) | JO3128B1 (es) |
LT (2) | LT3135656T (es) |
MA (1) | MA35268B1 (es) |
MD (1) | MD4538C1 (es) |
ME (2) | ME03375B (es) |
MX (1) | MX339552B (es) |
MY (1) | MY196998A (es) |
PE (2) | PE20141113A1 (es) |
PL (2) | PL2720989T3 (es) |
PT (2) | PT2720989T (es) |
RS (2) | RS58546B1 (es) |
SI (2) | SI3135656T1 (es) |
SM (1) | SMT201600383B (es) |
TW (3) | TWI614234B (es) |
WO (1) | WO2012176066A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ME03375B (me) | 2011-06-20 | 2020-01-20 | H Lundbeck As | Deuterizovani 1-piperazin0-3-fenil indani za tretiranje šizofrenije |
AR094054A1 (es) * | 2012-12-19 | 2015-07-08 | H Lundbeck As | 6-cloro-3-(fenil-d₅)-inden-1-ona y uso de la misma |
US11214545B2 (en) | 2017-09-07 | 2022-01-04 | Otsuka Pharmaceutical Co., Ltd. | Industrial process of mono-alkylating piperidine nitrogen in piperidine derivative with deuterated-lower-alkyl |
WO2020089147A1 (en) | 2018-10-29 | 2020-05-07 | H. Lundbeck A/S | Amorphous compounds of formula (i) and amorphous compounds of formula (i) salts |
JP2022509965A (ja) | 2018-12-03 | 2022-01-25 | ハー・ルンドベック・アクチエゼルスカベット | 4-((1R,3S)-6-クロロ-3-フェニル-2,3-ジヒドロ-1H-インデン-1-イル)-1,2,2-トリメチルピペラジン及び4-((1R,3S)-6-クロロ-3-(フェニル-d5)-2,3-ジヒドロ-1H-インデン-1-イル)-2,2-ジメチル-1-(メチル-d3)ピペラジンのプロドラッグ |
JP2022515156A (ja) * | 2018-12-21 | 2022-02-17 | テラン バイオサイエンシズ, インコーポレイテッド | ボリナンセリンの重水素化形態および誘導体 |
EP3939954A4 (en) * | 2019-03-13 | 2023-01-04 | Otsuka Pharmaceutical Co., Ltd. | METHOD FOR INTRODUCING A DEUTERED LOWER ALKYL INTO AN AMINE FRACTION OF A COMPOUND CONTAINING A SECONDARY AMINE |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE50867B1 (en) | 1980-02-29 | 1986-08-06 | Kefalas As | Indane derivatives |
GB8427125D0 (en) | 1984-10-26 | 1984-12-05 | Lundbeck & Co As H | Organic compounds |
DK286990D0 (da) | 1990-12-04 | 1990-12-04 | Lundbeck & Co As H | Indanderivater |
DK55192D0 (da) * | 1992-04-28 | 1992-04-28 | Lundbeck & Co As H | 1-piperazino-1,2-dihydroindenderivater |
DE69535592T2 (de) * | 1994-03-25 | 2008-06-12 | Isotechnika, Inc., Edmonton | Verbesserung der effektivität von arzneimitteln duren deuterierung |
US6221335B1 (en) | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
UA81749C2 (uk) | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
JP5043429B2 (ja) | 2003-08-18 | 2012-10-10 | ハー・ルンドベック・アクチエゼルスカベット | トランス−4−((1r,3s)−6−クロロ−3−フェニルインダン−1−イル)−1,2,2−トリメチルピペラジンのコハク酸塩およびマロン酸塩、および薬剤としての使用方法 |
EA200600443A1 (ru) * | 2003-08-18 | 2006-08-25 | Х. Лундбекк А/С | Транс-1-(6-хлор-3-фенилиндан-1-ил)-3,3-диметилпиперазин |
JP2008530039A (ja) | 2005-02-16 | 2008-08-07 | ハー・ルンドベック・アクチエゼルスカベット | トランス−1−((1r,3s)−6−クロロ−3−フェニルインダン−1−イル)−3,3−ジメチルピペラジンの酒石酸塩およびリンゴ酸塩 |
TWI376373B (en) | 2005-02-16 | 2012-11-11 | Lundbeck & Co As H | Crystalline base of a pharmaceutical compound |
TWI453198B (zh) | 2005-02-16 | 2014-09-21 | Lundbeck & Co As H | 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s)-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法 |
US7863274B2 (en) | 2005-07-29 | 2011-01-04 | Concert Pharmaceuticals Inc. | Deuterium enriched analogues of tadalafil as PDE5 inhibitors |
CN101273024A (zh) | 2005-07-29 | 2008-09-24 | 康瑟特制药公司 | 新颖苯并[d][1,3]-二氧杂环戊烯衍生物 |
EP1954669B1 (en) | 2005-12-01 | 2015-07-08 | Auspex Pharmaceuticals, Inc. | Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity |
JP4986462B2 (ja) | 2006-01-27 | 2012-07-25 | シャープ株式会社 | 太陽電池ストリングおよびその製造方法、ならびに、その太陽電池ストリングを用いる太陽電池モジュール |
TW200819426A (en) | 2006-08-31 | 2008-05-01 | Lundbeck & Co As H | Novel indane compounds |
WO2008128166A1 (en) | 2007-04-13 | 2008-10-23 | Concert Pharmaceuticals Inc. | Deuterated derivatives of 4-(6-fluoro-1, 2-benzisoxazol-3-yl) piperidine compounds |
US7528131B2 (en) | 2007-04-19 | 2009-05-05 | Concert Pharmaceuticals Inc. | Substituted morpholinyl compounds |
AU2008267048C1 (en) | 2007-06-12 | 2013-01-17 | Concert Pharmaceuticals, Inc. | Azapeptide derivatives |
US20090062303A1 (en) | 2007-08-29 | 2009-03-05 | Protia, Llc | Deuterium-enriched ziprasidone |
BRPI0912223A2 (pt) | 2008-05-07 | 2015-10-06 | Lundbeck & Co As H | métodos para melhorar funcionamento cognitivo e para tratar uma doença, composto, uso do mesmo, e, composição farmacêutica. |
EA201170512A1 (ru) | 2008-10-03 | 2011-08-30 | Х. Лундбекк А/С | Композиция для перорального введения |
US20120071554A1 (en) | 2008-10-28 | 2012-03-22 | Liu Julie F | Deuterated 2-propylpentanoic acid compounds |
US8263601B2 (en) | 2009-02-27 | 2012-09-11 | Concert Pharmaceuticals, Inc. | Deuterium substituted xanthine derivatives |
US8658236B2 (en) * | 2009-08-21 | 2014-02-25 | Deuteria Beverages, Llc | Alcoholic compositions having a lowered risk of acetaldehydemia |
CN102020522A (zh) * | 2009-09-21 | 2011-04-20 | 陈松源 | 氘代药物的制备方法和应用 |
US8278460B2 (en) | 2009-10-15 | 2012-10-02 | Concert Pharmaceuticals, Inc. | Substituted benzimidazoles |
WO2011059080A1 (ja) * | 2009-11-16 | 2011-05-19 | 第一三共株式会社 | 同位体置換されたジアミン誘導体 |
ME03375B (me) | 2011-06-20 | 2020-01-20 | H Lundbeck As | Deuterizovani 1-piperazin0-3-fenil indani za tretiranje šizofrenije |
-
2012
- 2012-06-19 ME MEP-2019-93A patent/ME03375B/me unknown
- 2012-06-19 SI SI201231582T patent/SI3135656T1/sl unknown
- 2012-06-19 AR ARP120102179 patent/AR086987A1/es active IP Right Grant
- 2012-06-19 KR KR1020137033717A patent/KR101879474B1/ko active IP Right Grant
- 2012-06-19 ES ES19151618T patent/ES2939477T3/es active Active
- 2012-06-19 PE PE2013002857A patent/PE20141113A1/es not_active Application Discontinuation
- 2012-06-19 CA CA2837820A patent/CA2837820C/en active Active
- 2012-06-19 GE GEAP201213350A patent/GEP201706655B/en unknown
- 2012-06-19 RS RS20190429A patent/RS58546B1/sr unknown
- 2012-06-19 SI SI201230744A patent/SI2720989T1/sl unknown
- 2012-06-19 WO PCT/IB2012/001386 patent/WO2012176066A1/en active Application Filing
- 2012-06-19 DK DK12748046.5T patent/DK2720989T3/en active
- 2012-06-19 ES ES12748046.5T patent/ES2601213T3/es active Active
- 2012-06-19 LT LTEP16179882.2T patent/LT3135656T/lt unknown
- 2012-06-19 AU AU2012273657A patent/AU2012273657B2/en active Active
- 2012-06-19 EP EP23150855.7A patent/EP4215512A1/en active Pending
- 2012-06-19 MD MDA20140004A patent/MD4538C1/ro active IP Right Grant
- 2012-06-19 PT PT127480465T patent/PT2720989T/pt unknown
- 2012-06-19 RS RS20160916A patent/RS55304B1/sr unknown
- 2012-06-19 PT PT16179882T patent/PT3135656T/pt unknown
- 2012-06-19 HU HUE16179882A patent/HUE044043T2/hu unknown
- 2012-06-19 LT LTEP12748046.5T patent/LT2720989T/lt unknown
- 2012-06-19 US US13/527,364 patent/US8575174B2/en active Active
- 2012-06-19 AP AP2013007338A patent/AP3310A/xx active
- 2012-06-19 PE PE2015000596A patent/PE20150928A1/es active IP Right Grant
- 2012-06-19 MX MX2013014849A patent/MX339552B/es active IP Right Grant
- 2012-06-19 PL PL12748046T patent/PL2720989T3/pl unknown
- 2012-06-19 EP EP12748046.5A patent/EP2720989B1/en active Active
- 2012-06-19 EP EP16179882.2A patent/EP3135656B1/en active Active
- 2012-06-19 PL PL16179882T patent/PL3135656T3/pl unknown
- 2012-06-19 MY MYPI2021002383A patent/MY196998A/en unknown
- 2012-06-19 BR BR112013031702-7A patent/BR112013031702B1/pt active IP Right Grant
- 2012-06-19 JP JP2014516459A patent/JP5668177B2/ja active Active
- 2012-06-19 EP EP19151618.6A patent/EP3508468B1/en active Active
- 2012-06-19 ES ES16179882T patent/ES2719145T3/es active Active
- 2012-06-19 HU HUE12748046A patent/HUE030883T2/en unknown
- 2012-06-19 DK DK16179882.2T patent/DK3135656T3/en active
- 2012-06-19 EA EA201490045A patent/EA024651B1/ru not_active IP Right Cessation
- 2012-06-19 ME MEP-2016-226A patent/ME02513B/me unknown
- 2012-06-19 JO JOP/2012/0161A patent/JO3128B1/ar active
- 2012-06-19 CN CN201280029731.8A patent/CN103649019B/zh active Active
- 2012-06-19 KR KR1020187018343A patent/KR101939546B1/ko active IP Right Grant
- 2012-06-20 TW TW106107563A patent/TWI614234B/zh active
- 2012-06-20 TW TW107113541A patent/TWI659741B/zh active
- 2012-06-20 TW TW101122028A patent/TWI627956B/zh active
-
2013
- 2013-06-24 US US13/924,849 patent/US9012453B2/en active Active
- 2013-11-26 IL IL229640A patent/IL229640B/en active IP Right Grant
- 2013-12-09 GT GT201300304A patent/GT201300304A/es unknown
- 2013-12-13 CR CR20130654A patent/CR20130654A/es unknown
- 2013-12-16 DO DO2013000305A patent/DOP2013000305A/es unknown
- 2013-12-19 CO CO13296680A patent/CO6821965A2/es active IP Right Grant
- 2013-12-19 CL CL2013003646A patent/CL2013003646A1/es unknown
-
2014
- 2014-01-16 MA MA36688A patent/MA35268B1/fr unknown
- 2014-01-17 EC ECSP14013155 patent/ECSP14013155A/es unknown
- 2014-10-22 HK HK14110519A patent/HK1197228A1/zh unknown
-
2015
- 2015-03-13 US US14/656,925 patent/US9216961B2/en active Active
- 2015-11-16 US US14/941,800 patent/US9617231B2/en active Active
-
2016
- 2016-10-17 HR HRP20161348TT patent/HRP20161348T1/hr unknown
- 2016-10-26 SM SM201600383T patent/SMT201600383B/it unknown
- 2016-10-26 CY CY20161101089T patent/CY1118158T1/el unknown
-
2017
- 2017-02-17 US US15/435,826 patent/US10118907B2/en active Active
-
2018
- 2018-09-28 US US16/146,625 patent/US10501427B2/en active Active
-
2019
- 2019-03-27 HR HRP20190593TT patent/HRP20190593T1/hr unknown
- 2019-04-02 CY CY20191100368T patent/CY1121514T1/el unknown
- 2019-11-04 US US16/672,870 patent/US11059798B2/en active Active
-
2021
- 2021-06-07 US US17/340,201 patent/US20220119362A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2013003646A1 (es) | Compuestos derivados de trans-1-(3s.1r)-6-cloro-3-fenilindan-1-il)-1,2,2-trimetilpiperazina deuterados, con actividad en los receptores 5ht2, d1 y d2; proceso de preparacion; compuesto intermediario; composicion y combinacion farmaceutica; y su uso para el tratamiento de la psicosis, entre otros. | |
UY32462A (es) | Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644 | |
DOP2012000151A (es) | Nuevos compuestos triciclicos | |
DOP2012000243A (es) | Compuestos de sililo tricíclicos fusionados y uso de los mismos en la fabricación de medicamentos útiles en el tratamiento de enfermedades virales | |
CU20170144A7 (es) | Compuestos de tetrahidroquinolinona sustituidos como moduladores gamma ror | |
ECSP14013221A (es) | Fenil-3-aza-biciclo [3.1.0] hex-3-il-metanonas y su uso como medicamento. | |
PE20142285A1 (es) | Derivados de imidazotiadiazol e imidazopirazina como inhibidores del receptor activado de proteasa 4 (par4) para el tratamiento de agregacion plaquetaria | |
CO6670589A2 (es) | Compuestos para reducir la producción de beta-amiloide | |
CR20130560A (es) | Compuestos de bezotiazol y su uso farmacéutico | |
DOP2014000121A (es) | Derivados de betulina | |
AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
UY33183A (es) | Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento | |
EA201390908A1 (ru) | Производные бицикло[3.2.1]октиламида и их применение | |
EA201001595A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
BR112015010791A2 (pt) | moduladores de gpr40 de di-hidropirazol | |
UY32240A (es) | Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones. | |
EA201500298A1 (ru) | Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы | |
UY31885A (es) | Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones. | |
CR20130693A (es) | Composición farmacéutica ortalmológica tópica que contiene regorafenib | |
EA201792594A1 (ru) | Положительные аллостерические модуляторы мусаринового рецептора м1 | |
EA201890684A1 (ru) | Производные фториндола в качестве положительных аллостерических модуляторов мускаринового рецептора m1 | |
UY32744A (es) | Derivados de 2-carboxamida-7-piperazinil-benzofurano 774 | |
ECSP13012548A (es) | Inhibidores de oxadiazol de la producción de leucotrienos. | |
AR071721A1 (es) | Derivados de piridil-prolinamida, composiciones farmaceuticas que los contienen y su uso para el tratamiento de ansiedad, depresion y trastornos del sueno. | |
CR20190014A (es) | Derivados etinilo |